CER-209 / Abionyx Pharma - LARVOL DELTA

Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study. (PubMed, Breast Cancer (Dove Med Press)) - "Out of 216 women with breast cancer 209 participated in the study with a response rate of 97%...Getting social support (OR=3.959, 95%CI: 1.570-9.980), being on anastrozole (OR=0.139, 95%CI: 0.040-0.485), getting a thorough therapeutic communication about treatment (OR=4.590, 95%CI: 1.061-19.863), undergoing mastectomy (OR=0.215, 95%CI: 0.059-0.788), having side effects (OR=0.210, 95%CI: 0.085-0.517) were found to be significantly associated with adherence to AHT. In general, the overall adherence to AHT was 77.5% for women with breast cancer. Factors such as types of adjuvant hormone therapy, lack of side effects, mastectomy, getting social support, and thorough therapeutic communication were strongly linked with adherence to them."

Clinical • Journal • Observational data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Cerenis Therapeutics: 2018 Annual results and clinical update (Businesswire) - "In order to activate this potential and finance the CER-209...CERENIS is currently assessing the best strategic opportunities....The next steps will include the development of a formulation with optimal bioavailability in preparation for a Phase II clinical study in patients with NASH over a longer period of time."

Financing • New P2 trial